Expected Moves

Nov 12, 2026→Nov 26, 2026

Dec 10, 2026→Dec 24, 2026

Expected clinical or regulatory pipeline milestone update regarding core hyaluronic acid-based therapeutic applications.

Feb 11, 2027→Feb 25, 2027

Fiscal Q3 financial results reflecting seasonal demand in elective orthopedic procedures.

Mar 25, 2027→Apr 8, 2027

Potential corporate governance update regarding share buybacks or special dividends prior to the fiscal year end.

May 13, 2027→May 27, 2027

Announcement of full-year financial outcomes and the establishment of FY2027 forward guidance.